

Contents

Preface	xix
Comments on the book <i>Extracellular Matrix: Pathobiology & Signaling</i> by Dick Heinegård	xxiii
About the Editor/Section Editors	xxv
List of contributing authors	xxix
Abbreviations and acronyms used	xxxix
 1 An introduction to the extracellular matrix molecules and their importance in pathobiology and signaling	1
1.1 Extracellular matrix: a functional scaffold	3
<i>Achilleas Theocharis, Chrisostomi Gialeli, Vincent Hascall, and Nikos Karamanos</i>	
1.1.1 ECM components: structural and functional properties	4
1.1.2 Matrix remodeling is accomplished by proteolytic enzymes	12
1.1.3 Cell surface receptors mediate cell-cell and cell-matrix interactions	14
1.1.4 Take-home message	17
 2 Insights into the function of glycans	21
2.1 Introduction	23
<i>Paraskevi Heldin</i>	
2.2 Metabolic control of hyaluronan synthesis	26
<i>Alberto Passi, Giancarlo De Luca, Evgenia Karousou, Davide Vigetti, and Manuela Viola</i>	
2.2.1 Introduction	26
2.2.2 Transcription of hyaluronan synthases	27
2.2.3 UDP-sugar substrates as limiting factors in hyaluronan synthesis ..	29
2.2.4 Posttranslational processing of HAS	32
2.2.5 Challenges and future prospects	35
2.2.6 Take-home message	35
 2.3 Multiple roles of hyaluronan as a target and modifier of the inflammatory response	39
<i>Sanna Oikari, Tiina A. Jokela, Raija H. Tammi, and Markku I. Tammi</i>	
2.3.1 Introduction	39
2.3.2 Endothelial permeability	40

2.3.3	Angiogenesis	40
2.3.4	Mechanisms of hyaluronan degradation	41
2.3.5	Consequences of hyaluronan fragmentation	41
2.3.6	Hyaluronan cross-talk with leukocytes	42
2.3.7	Adhesion of leukocytes to hyaluronan	46
2.3.8	Hyaluronan removal in the late phase of inflammation	48
2.3.9	Local clearance of hyaluronan	48
2.3.10	Chronic inflammation	49
2.3.11	Hyaluronan increase in wounds	50
2.3.12	Support of migration and proliferation	51
2.3.13	TGF- β and myofibroblasts	52
2.3.14	Therapeutic applications	53
2.3.15	Future perspectives	53
2.3.16	Take-home message	54
2.4	Roles of sulfated and nonsulfated glycosaminoglycans in cancer growth and progression-therapeutic implications	66
	<i>Dragana Nikitovic and George N. Tzanakakis</i>	
2.4.1	Introduction	66
2.4.2	Heparin and heparan sulfate affect key tumor cell functions	67
2.4.3	Chondroitin sulfate participates in cancer cell, tumor stroma, and tumor microenvironment interactions to affect cancer progression	70
2.4.4	HA synthesis is correlated to cancer progression	72
2.4.5	Challenges and future prospects	74
2.4.6	Take-home message	76
2.5	Heparan sulfate design: regulation of biosynthesis	84
	<i>Dagmar S. Pikas, Anh-Tri Do, Audrey Deligny, Anders Dagälv, and Lena Kjellén</i>	
2.5.1	Heparan sulfate – an extracellular component with variable structure	84
2.5.2	How is heparan sulfate synthesized and which enzymes contribute?	85
2.5.3	Fine-tuning of heparan sulfate structure in the right place, at the right time	88
2.5.4	Disturbed heparan sulfate biosynthesis in human pathobiology ...	92
2.5.5	Take-home message	93
2.6	Bone and skin disorders caused by a disturbance in the biosynthesis of chondroitin sulfate and dermatan sulfate	98
	<i>Shuji Mizumoto and Kazuyuki Sugahara</i>	
2.6.1	Introduction	98
2.6.2	Biosynthetic pathways of CS and DS chains	100
2.6.3	Human congenital disorders caused by mutations of the enzymes involved in the biosynthesis of CS and DS	105

2.6.4	Challenges and future prospects	108
2.6.5	Take-home message	112
2.6.6	Abbreviations	112
2.7	Biological functions of branched <i>N</i> -glycans related to physiology and pathology of extracellular matrix	119
	<i>Congxiao Gao, Kazuaki Ohtsubo, Jianguo Gu, and Naoyuki Taniguchi</i>	
2.7.1	Introduction	119
2.7.2	Synthesis of branched <i>N</i> -glycans	119
2.7.3	Effect of <i>N</i> -glycosylation on ECM formation	122
2.7.4	Complexity of <i>N</i> -glycan branch modulates cellular functions via clustering cell surface proteins	123
2.7.5	Branched <i>N</i> -glycans regulate the biological functions of integrins	124
2.7.6	The mutual regulation of <i>N</i> -glycosylation and cadherins	125
2.7.7	Challenges and future prospects	126
2.7.8	Take-home message	127
3	Proteoglycans: structure, pathobiology, and signaling	133
3.1	Introduction	135
	<i>Liliana Schaefer</i>	
3.2	Aggrecan in skeletal development and regenerative medicine	141
	<i>Anna Plaas, Daniel J. Gorski, Jennifer Velasco, Colton McNicols, Rebecca Bell, Vincent Wang, and John Sandy</i>	
3.2.1	Introduction	141
3.2.2	Aggrecan in skeletal development	141
3.2.3	Aggrecan in regenerative medicine	144
3.2.4	Take-home message	148
3.3	The pathobiology of versican	154
	<i>Thomas N. Wight</i>	
3.3.1	Introduction	154
3.3.2	Cardiovascular disease	154
3.3.3	Cancer	159
3.3.4	Lung	161
3.3.5	Eye	161
3.3.6	Concluding remarks	162
3.3.7	Take-home message	163
3.4	The biology of perlecan and its bioactive modules	171
	<i>Chris D. Willis, Liliana Schaefer, and Renato V. Iozzo</i>	
3.4.1	Introduction	171
3.4.2	Discovery	171
3.4.3	Expression and localization	171

3.4.4	Protein family.	172
3.4.5	The <i>HSPG2</i> gene	172
3.4.6	Domain structure and known interactions	173
3.4.7	Genetic links to diseases	176
3.4.8	Genetic models	176
3.4.9	Perlecan role in cancer	177
3.4.10	Perlecan role in vascular biology and angiogenesis	178
3.4.11	Conclusions and future directions.	180
3.4.12	Take-home message	181
3.5	Small leucine-rich proteoglycans: multifunctional signaling effectors.	185
	<i>Rosetta Merline, Madalina V. Nastase, Renato V. Iozzo, and Liliana Schaefer</i>	
3.5.1	Introduction.	185
3.5.2	Physiological functions	185
3.5.3	Pathobiology of class I SLRPs.	186
3.5.4	Pathobiology of class II SLRPs	189
3.5.5	Pathobiology of class III SLRPs.	190
3.5.6	Take-home message	191
3.6	Structure and function of syndecans	197
	<i>Csilla Pataki and John R. Couchman</i>	
3.6.1	Syndecan structure	197
3.6.2	Function of syndecans	199
3.6.3	Syndecan domains and their roles	201
3.6.4	Take-home message	204
3.7	The glypican family.	209
	<i>Jorge Filmus and Mariana Capurro</i>	
3.7.1	The structure of glypicans	209
3.7.2	The functions of glypicans.	210
3.7.3	Pathobiology of glypicans	214
3.7.4	Future research	216
3.7.5	Take-home message	216
3.8	Serglycin proteoglycan: implications for thrombosis, inflammation, atherosclerosis, and metastasis	221
	<i>Barbara P. Schick</i>	
3.8.1	Introduction.	221
3.8.2	Cloning and cell and tissue localization of serglycin	221
3.8.3	Cell-specific serglycin structure	222
3.8.4	Regulation of serglycin expression	222
3.8.5	Binding of cell-specific serglycin to biologically active proteins.	222
3.8.6	Serglycin in hematopoietic cells.	223
3.8.7	Serglycin in nonhematopoietic cells	224
3.8.8	The serglycin knockout mouse.	225

3.8.9	Challenges and future prospects	227
3.8.10	Take-home message	228
4	Matrix proteinases: biological significance in health and disease	233
4.1	Introduction	235
	<i>Jan-Olof Winberg</i>	
4.2	Extracellular functions of cysteine proteases	239
	<i>Harald Thidemann Johansen and Rigmor Solberg</i>	
4.2.1	Introduction	239
4.2.2	Cysteine proteases and their inhibitors	240
4.2.3	Endogenous inhibitors of cysteine proteases	241
4.2.4	Cysteine proteases and their inhibitors in diseases	244
4.2.5	Pharmacological targeting of cysteine proteases	251
4.2.6	Take-home message	253
4.3	Plasmin and the plasminogen activator system in health and disease	261
	<i>Gunbjørg Svineng, Synnøve Magnussen, and Elin Hadler-Olsen</i>	
4.3.1	Introduction	261
4.3.2	Plasmin	261
4.3.3	Plasminogen activators	266
4.3.4	Inhibitors of plasminogen activators	270
4.3.5	Plasmin substrates	271
4.3.6	Inhibitors of plasmin	274
4.3.7	Plasmin system in cancer	275
4.3.8	Take-home message	277
4.4	Matrix metalloproteinase complexes and their biological significance	291
	<i>Bodil Fadnes, Elin Hadler-Olsen, Ingebrigt Sylte, Lars Uhlin-Hansen, and Jan-Olof Winberg</i>	
4.4.1	Introduction	291
4.4.2	MMP structure and classification	293
4.4.3	MMP complexes	294
4.4.4	Take-home message	308
4.5	The ADAMTS family of metalloproteinases	315
	<i>Hideaki Nagase</i>	
4.5.1	Introduction	315
4.5.2	The ADAMTS family	317
4.5.3	Three-dimensional structures of ADAMTSs	320
4.5.4	Procollagen N-proteinases (ADAMTS2, 3, and 14)	322
4.5.5	Aggrecanases	323
4.5.6	Inhibition of angiogenesis by ADAMTSs	327
4.5.7	Von Willebrand factor-cleaving proteinase: ADAMTS13	328

4.5.8	ADAMTS18 and dissolution of platelet aggregates	329
4.5.9	Atherosclerosis	330
4.5.10	ADAMTSs and morphogenesis	330
4.5.11	Wound healing	332
4.5.12	Ovulation	333
4.5.13	Future prospects	334
4.5.14	Take-home message	334
4.6	Proteinases in wound healing	343
	<i>Mervi Toriseva and Veli-Matti Kähäri</i>	
4.6.1	Introduction	343
4.6.2	Overview of cutaneous wound repair	343
4.6.3	Hemostasis and inflammation	344
4.6.4	Reepithelialization	345
4.6.5	Granulation tissue formation	345
4.6.6	Tissue remodeling and wound maturation	346
4.6.7	Growth factors and cytokines regulating cutaneous wound healing	346
4.6.8	Proteolysis in cutaneous wound healing	348
4.6.9	PA-plasmin system	348
4.6.10	Matrix metalloproteinases	351
4.6.11	ADAM proteinases	356
4.6.12	ADAMTS proteinases	357
4.6.13	TIMPs and chemical targeting of metalloproteinases	358
4.6.14	Proteolysis in aberrant cutaneous wound healing	359
4.6.15	Targeting proteolysis – applications for wound-healing therapy	363
4.6.16	Take-home message	364
4.7	Rock, paper, and molecular scissors: regulating the game of extracellular matrix homeostasis, remodeling, and inflammation	377
	<i>Antoine Dufour and Christopher M. Overall</i>	
4.7.1	Proteases	377
4.7.2	Matrix metalloproteinases	378
4.7.3	Natural inhibitors of MMPs	380
4.7.4	MMPs in cancer	381
4.7.5	MMPs in Inflammation	383
4.7.6	MMP inhibitors and clinical trials	384
4.7.7	The protease web	385
4.7.8	Degradomics	385
4.7.9	The CLIP-CHIP, a dedicated and focused microarray for every protease and inhibitor	386
4.7.10	Classic biochemical approaches	386
4.7.11	Sodium dodecyl sulfate polyacrylamide gel electrophoresis, zymography, mass spectrometry, and high-performance liquid chromatography	387
4.7.12	Proteomic identification of protease cleavage site specificity	388

4.7.13	Yeast two-hybrid analyses: exosite scanning and inactive-catalytic-domain capture	388
4.7.14	Amino-terminal-oriented mass spectrometry of substrates	389
4.7.15	Quantitative N- and C-terminal proteomics for substrate discovery	389
4.7.16	N-terminal combined fractional diagonal chromatography	390
4.7.17	N-terminal amine isotopic labeling of substrates	391
4.7.18	C terminomics and C-terminal amine-based isotope labeling of substrates	392
4.7.19	Perspectives and Take-home message	393
5	ECM cell surface receptors	401
5.1	Introduction <i>Donald Gullberg</i>	403
5.2	Integrin function in heart fibrosis: mechanical strain, transforming growth factor-beta 1 activation, and collagen glycation <i>Boris Hinz and Christopher A. McCulloch</i>	406
5.2.1	Introduction	406
5.2.2	Cardiac fibrosis – the players	407
5.2.3	ECM posttranslational modifications in fibrosis: type 1 and type 2 diabetes	411
5.2.4	Interaction of integrins with glycosylated collagen	415
5.2.5	TGF- β and integrins – a close relationship	417
5.2.6	Conclusions	421
5.2.7	Take-home message	421
5.3	Cancer-associated fibroblast integrins as therapeutic targets in the tumor microenvironment <i>Ning Lu, Cord Brakebusch and Donald Gullberg</i>	432
5.3.1	Introduction	432
5.3.2	CAF Biology	432
5.3.3	Integrins on CAFs	433
5.3.4	Integrin function on CAF precursors	438
5.3.5	Integrin function in CAF differentiation	439
5.3.6	CAF integrins and tumor cell proliferation	441
5.3.7	Integrin function in CAF-promoted invasion and metastasis	441
5.3.8	Summary	444
5.4	Discoidin domain receptors: non-integrin collagen receptors on the move <i>Antonio S. Rocca and Michelle P. Bendeck</i>	451
5.4.1	Introduction	451
5.4.2	Collagen and collagen receptors	451
5.4.3	Discoidin domain receptor subfamily of receptor tyrosine kinases	454

5.4.4	Functions of DDRs	458
5.4.5	Conclusions	462
5.4.6	Take-home message	462
5.5	Syndecans as receptors for pericellular molecules	467
	<i>Xiaojie Xian, James R. Whiteford, and John R. Couchman</i>	
5.5.1	Introduction	467
5.5.2	Syndecans as cell surface ECM receptors	469
5.5.3	Syndecans as receptors mediating endocytosis	473
5.5.4	Syndecans as receptors for growth factors and chemokines	473
5.5.5	Perspective – specificity of syndecans and their signaling responses	477
5.5.6	Take-home message	478
5.6	CD44: a Sensor of tissue damage critical for restoring homeostasis	484
	<i>Ellen Puré</i>	
5.6.1	Introduction	484
5.6.2	CD44 structure and processing	485
5.6.3	Hyaluronan and other ligands of CD44	485
5.6.4	CD44-mediated signaling	486
5.6.5	CD44 function in mesenchymal stromal cells	487
5.6.6	CD44 function in leukocytes	491
5.6.7	Role of CD44 in the resolution of inflammation	492
5.6.8	CD44 in disease and as a potential therapeutic target	492
5.6.9	Concluding remarks	493
5.6.10	Take-home message	494
6	Collagen: insights into the folding, assembly and functions	499
6.1	Introduction	501
	<i>Ruggero Tenni</i>	
6.2	Trimerization domains in collagens: chain selection, folding initiation, and triple-helix stabilization	506
	<i>Sergei P. Boudko and Hans Peter Bächinger</i>	
6.2.1	Introduction	506
6.2.2	Chain selection and trimerization	507
6.2.3	Trimerization domains and triple-helix folding and stabilization	513
6.2.4	Pathologies associated with trimerization domains	514
6.2.5	Future prospects and challenges	515
6.2.6	Take-home message	516
6.3	Structural basis of collagen missense mutations	521
	<i>Anton V. Persikov and Barbara Brodsky</i>	
6.3.1	Introduction: collagens and disease	521
6.3.2	Peptide models of collagen mutations	521
6.3.3	Computational analysis	528

6.3.4	Collagen mutations in a recombinant bacterial system	530
6.3.5	Summary and take-home message	535
6.4	Roles and regulation of BMP1/Tolloid-like proteinases: collagen/matrix assembly, growth factor activation, and beyond	539
	<i>Catherine Moali and David J. S. Hulmes</i>	
6.4.1	Introduction	539
6.4.2	BMP1/Tolloid-like proteinases	539
6.4.3	Substrates	542
6.4.4	Endogenous regulators of activity	550
6.4.5	Meprins and matrix assembly	554
6.4.6	Conclusions and take-home message	555
6.5	Supramolecular assembly of type I collagen	562
	<i>Mario Raspanti</i>	
6.5.1	Introduction	562
6.5.2	The multimodal fibrils: tendon, bone, and ligaments	563
6.5.3	The unimodal fibrils: cornea, sheaths, and blood vessels	567
6.5.4	Take-home message	571
6.6	Collagen interactomes: mapping functional domains and mutations on fibrillar and network-forming collagens	575
	<i>James D. San Antonio, J. Des Parkin, Judy Savige, Joseph P. R. O. Orgel, and Olena Jacenko</i>	
6.6.1	Collagen interactomes	575
6.6.2	Type I collagen interactome	576
6.6.3	Type IV collagen interactome	582
6.6.4	Type III collagen interactome	586
6.6.5	Type II collagen	587
6.6.6	Type X collagen	587
6.6.7	Future perspectives	588
6.6.8	Take-home message	588
6.7	Collagen-binding proteins	592
	<i>Takako Sasaki</i>	
6.7.1	Introduction	592
6.7.2	Heat-shock protein-47	593
6.7.3	Pigment epithelium-derived factor	594
6.7.4	Fibronectin	595
6.7.5	Von Willebrand factor	596
6.7.6	Glycoprotein VI	596
6.7.7	Leukocyte-associated immunoglobulin-like receptor-1	597
6.7.8	Discoidin domain receptors (DDR)	597
6.7.9	Secreted protein acidic and rich in cysteine	598
6.7.10	Take-home message	600

7. Emerging aspects in extracellular matrix pathobiology	603
7.1 Introduction	605
<i>Achilleas Theocharis</i>	
7.2 Extracellular matrix in breast cancer: permissive and restrictive influences emanating from the stroma.	610
<i>Ida Pucci-Minafra</i>	
7.2.1 Introduction.	610
7.2.2 The extracellular context in the mammary gland	610
7.2.3 The physical role of connective tissue stroma	613
7.2.4 The proteomic lesson	616
7.2.5 Concluding remarks	619
7.2.6 Challenges and future prospects.	621
7.2.7 Take-home message	621
7.3 EMMPRIN/CD147: potential functions in tumor microenvironment and therapeutic target for human cancer	626
<i>Eric Huet, Eric E Gabison, Samia Mourah, and Suzanne Menashi</i>	
7.3.1 Introduction.	626
7.3.2 Protease-inducing activity of EMMPRIN: role in tumor cell invasion.	629
7.3.3 Role of EMMPRIN in myofibroblast differentiation	630
7.3.4 Role of EMMPRIN in angiogenesis	631
7.3.5 Shedding of EMMPRIN	632
7.3.6 EMMPRIN as a therapeutic target for human cancer.	633
7.3.7 Take-home message	634
7.4 Implication of hyaluronidases in cancer growth, metastasis, diagnosis, and treatment	639
<i>Irene-Eva Triantaphyllidou, Serafoula Filou, Helen Bouga, Constantine Kolliopoulos, and Demitrios H. Vynios</i>	
7.4.1 Introduction.	639
7.4.2 Hyaluronidases in cancer	640
7.4.3 Regulation of hyaluronidase activity	643
7.4.4 Hyaluronidases and cell cycle progression	644
7.4.5 Anticancer properties of hyaluronidases	646
7.4.6 Further medical applications of hyaluronidases	648
7.4.7 Challenges and future prospects.	649
7.4.8 Take-home message	649
7.5 Structure-function relationship of syndecan-1, with focus on nuclear translocation and tumor cell behavior	653
<i>Fang Zong, Ilona Kovalszky, Anders Hjerpe, and Katalin Dobra</i>	
7.5.1 Syndecans	653
7.5.2 Structural organization	653

7.5.3	Functional domains and cellular interactions	654
7.5.4	Cellular distribution and nuclear translocation	656
7.5.5	Nuclear interactions	658
7.5.6	Syndecan-1 expression in normal tissues	660
7.5.7	Syndecan-1 in cancers	661
7.5.8	Syndecan expression affects tumor cell behavior	664
7.5.9	Potential for translation	666
7.5.10	Take-home message	668
7.6	Serglycin: a novel player in the terrain of neoplasia	677
	<i>Angeliki Korpetinou, Eleni Milia-Argeiti, Vassiliki Labropoulou,</i> <i>and Achilleas Theocharis</i>	
7.6.1	Introduction	677
7.6.2	Expression of serglycin in malignancies	678
7.6.3	Regulation of serglycin gene expression	679
7.6.4	Functional importance of serglycin in malignancies	679
7.6.5	Serglycin regulates the secretion of proteolytic enzymes	682
7.6.6	Serglycin regulates the secretion and properties of inflammatory mediators	683
7.6.7	Take-home message	685
7.7	Quantifying cell-ECM pathobiology in 3D	689
	<i>Joseph S. Maffei and Muhammad H. Zaman</i>	
7.7.1	Introduction	689
7.7.2	Importance of three-dimensional culture systems	689
7.7.3	Advancements in 3D quantification	692
7.7.4	Future directions	697
7.7.5	Take-home message	698
7.8	Diabetic foot infections	703
	<i>Cecilia Rydén</i>	
7.8.1	Introduction	703
7.8.2	Serological diagnosis of osteitis in foot infection in diabetes mellitus	708
7.8.3	Conclusion and summary	710
7.8.4	Take-home message	710
8	Targeting tumor microenvironment at the ECM level	717
8.1	Introduction	719
	<i>Nikos K. Karamanos</i>	
8.2	Targeting the tumor microenvironment in cancer progression	723
	<i>Suniti Misra, Vincent C. Hascall, Nikos K. Karamanos, Roger R. Markwald,</i> <i>and Shibnath Chatak</i>	
8.2.1	Targeting the tumor microenvironment	723

8.2.2	Cancer stem cells	728
8.2.3	Tumor angiogenesis: new concepts about the tumor microenvironment	731
8.2.4	CD44 in tumor biology	732
8.2.5	Take-home message	736
8.3	Growth factor signaling and extracellular matrix	741
	<i>Dragana Nikitovic, Harris Pratsinis, Aikaterini Berdiaki, Chrisostomi Gialeli, Dimitris Kletsas, and George N. Tzanakakis</i>	
8.3.1	Introduction	741
8.3.2	Interplay of growth factors and ECM	741
8.3.3	Growth factor signaling regulates ECM composition	744
8.3.4	Effect of ECM on growth factor action	749
8.3.5	Pharmacological Interventions	751
8.3.6	Take-home message	753
8.4	Targeting protein-glycan interactions at cell surface during EMT and hematogenous metastasis: consequences on tumor invasion and metastasis	763
	<i>Mauro S. G. Pavao, Eliene O. Kozłowski, and Felipe C.O.B. Teixeira</i>	
8.4.1	Introduction	763
8.4.2	Tumor invasion and metastasis	765
8.4.3	Unique glycosaminoglycans from marine invertebrates and their potential antitumor activity	772
8.4.4	Challenges and future prospects	775
8.4.5	Take-home message	776
8.5	Pharmacological targeting of proteoglycans and metalloproteinases: an emerging aspect in cancer treatment	785
	<i>Spyros S. Skandalis, Chrisostomi Gialeli, Nikos Afratis, Alexios J. Aletras, Theodore Tsegenidis, Achilleas D. Theocharis, and Nikos K. Karamanos</i>	
8.5.1	Introduction	785
8.5.2	The importance of targeting at ECM level in tumor progression	785
8.5.3	Pharmacological targeting of proteoglycans	786
8.5.4	Pharmacological targeting of matrix metalloproteinases	792
8.5.5	Pharmacological targeting of PGs/MMPs at the proteasome level	795
8.5.6	Concluding remarks	796
8.5.7	Take-home message	797
8.6	Targeting syndecan shedding in cancer	802
	<i>Ralph D. Sanderson and John R. Couchman</i>	
8.6.1	Introduction	802
8.6.2	Syndecan sheddases	803
8.6.3	Tissue inhibitors of metalloproteinases	804
8.6.4	Syndecan shedding and cancer	804

8.6.5	Future prospects	808
8.6.6	Take-home message	809
8.7	PG receptors with phosphatase action in cancer and angiogenesis	813
	<i>Marina Koutsioumpa and Evangelia Papadimitriou</i>	
8.7.1	Introduction	813
8.7.2	Glycosylated transmembrane protein phosphatase receptors	815
8.7.3	RPTP- β/ζ	817
8.7.4	Conclusions	820
8.7.5	Take-home message	820
8.8	Heparanase, a multifaceted protein involved in cancer, chronic inflammation, and kidney dysfunction	824
	<i>Israel Vlodavsky, Michael Elkin, Benito Casu, Jin-Ping Li, Ralph D. Sanderson, and Neta Ilan</i>	
8.8.1	Introduction	824
8.8.2	Involvement of heparanase in cancer progression	828
8.8.3	Heparanase and inflammation	836
8.8.4	Heparanase and diabetic nephropathy	840
8.8.5	Challenges and future perspectives	842
8.8.6	Take-home message	843
8.9	Delivery systems targeting cancer at the level of ECM	855
	<i>Shibnath Ghatak, Vincent C. Hascall, Nikos K. Karamanos, Roger R. Markwald, and Suniti Misra</i>	
8.9.1	Introduction	855
8.9.2	Targeting cancer	857
8.9.3	CD44-HA in tumor biology	860
8.9.4	Strategies that target CD44 to perturb HA-CD44 interaction in tumors	863
8.9.5	Take-home message	868
	Index	873